Hirz, Taghreed http://orcid.org/0000-0001-9230-1756
Mei, Shenglin http://orcid.org/0000-0001-8258-5898
Sarkar, Hirak
Kfoury, Youmna
Wu, Shulin
Verhoeven, Bronte M.
Subtelny, Alexander O.
Zlatev, Dimitar V.
Wszolek, Matthew W.
Salari, Keyan http://orcid.org/0000-0001-7940-4558
Murray, Evan
Chen, Fei http://orcid.org/0000-0003-2308-3649
Macosko, Evan Z. http://orcid.org/0000-0002-2794-5165
Wu, Chin-Lee
Scadden, David T.
Dahl, Douglas M.
Baryawno, Ninib http://orcid.org/0000-0001-6054-4163
Saylor, Philip J. http://orcid.org/0000-0003-4849-3695
Kharchenko, Peter V. http://orcid.org/0000-0002-6036-5875
Sykes, David B. http://orcid.org/0000-0002-9788-0221
Article History
Received: 15 April 2022
Accepted: 26 January 2023
First Online: 7 February 2023
Competing interests
: A.O.S. own shares in TScan Therapeutics and BioNTech. P.V.K. serves on the Scientific Advisory Board to Celsius Therapeutics Inc. and Biomage Inc. P.V.K. is an employee of Altos Labs. D.T.S. is a founder, director, and stockholder of Magenta Therapeutics, Clear Creek Bio, and LifeVaultBio. He is a director and stockholder of Agios Pharmaceuticals and Editas Medicines and a founder and stockholder of Fate Therapeutics and Geruda Therapeutics. He is a consultant for FOG Pharma, Inzen Therapeutics, ResoluteBio, and VCanBio and receives sponsored research support on an unrelated project from Sumitomo Dianippon. D.B.S. is a founder, consultant, and shareholder for Clear Creek Bio. K.S. is a recipient of sponsored research funding from Convergent Genomics. F.C. and E.Z.M. are consultants for Atlas Bio, inc. The remaining authors declare no competing interests.